Livzon MAB's Lecankitug injection accepted for NMPA review

Livzon Pharmaceutical Group Inc. announced its controlling subsidiary, Livzon MABPharm Inc., has received NMPA acceptance for the marketing authorization application of Lecankitug Injection. This drug, co-developed with Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., is an innovative dual IL-17A/F inhibitor intended for adults with moderate-to-severe plaque psoriasis.

Clinical trial results for Lecankitug Injection, announced in July 2025, showed superiority over secukinumab, demonstrating rapid onset, excellent short-term efficacy, long-lasting durability, and a favorable safety profile. The cumulative direct investment in research and development for Lecankitug Injection currently stands at approximately RMB 204.03 million.

As of this announcement, no IL-17A/F targeting product for psoriasis has been approved for marketing in China. However, domestic terminal sales value for single-target IL-17A and IL-17RA drugs in 2024 was RMB 2.833 bn. The review and approval timeline for Lecankitug Injection remains uncertain.